Sido Muncul’s President Director of Herbal Medicine and Pharmaceutical Industry<\/strong>, David Hidayat, recently revealed that the company is targeting revenue growth and net profit of low single-digit<\/em> during 2025. What makes Sido Muncul confident with this projection? Let’s dive deeper!<\/p>\n In order to achieve this target, SIDO plans to release various new herbal products<\/strong>. The domestic market is their main focus, but that’s not all. They will also increase the export contribution. In this scheme, it is important to remember that Sido Muncul has budgeted capex<\/em><\/strong> of around 150\u2013175 billion rupiah for 2025, compared to the 2024 allocation of 150\u2013200 billion rupiah. This allocation will be used for the maintenance of production facilities and technology development<\/strong>, which is expected to increase efficiency and innovation in their product lines.<\/p>\n Not only thinking about the future, David also expressed high optimism about SIDO’s performance during 2024. He believes that SIDO will achieve an annual net profit target of more than +10% YoY<\/strong>. This is quite an encouraging number, isn’t it? Given the challenges that exist in the current market, a positive performance in the coming year will be a good signal for investors.stocks and discuss with other investor communities.<\/p>\n Source: KONTAN<\/a><\/p>\nSIDO Strategy in 2025<\/h2>\n
Optimism in 2024<\/h2>\n